Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment

Clinical Microbiology and Infection

Volumn 24, Issue 7, 2018, Pages 780.e1-780.e3

  Allegretti, J R ^a   Allegretti, A S ^b   Phelps, E ^c   Xu, H ^c   Kassam, Z ^d,e   Fischer, M ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c INDIANA UNIVERSITY   (United States)

^d Open Biome   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Asymptomatic carriage; Clostridium difficile; Diarrhoea; Fecal microbiota transplantation; Infection control

Indexed keywords

ARTICLE; ASYMPTOMATIC INFECTION; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLONOSCOPY; DIARRHEA; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGMOIDOSCOPY; TREATMENT FAILURE; BACTERIAL GENE; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; FECES; GENETICS; HETEROZYGOTE; INDIANA; ISOLATION AND PURIFICATION; MASSACHUSETTS; MICROBIOLOGY; MULTICENTER STUDY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER; TREATMENT OUTCOME;

BACTERIAL DNA;

CARRIER STATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLONOSCOPY; DNA, BACTERIAL; FECAL MICROBIOTA TRANSPLANTATION; FECES; GENES, BACTERIAL; HUMANS; INDIANA; MASSACHUSETTS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RECURRENCE; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 85036533299     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.10.022     Document Type: Article

References (14)

1. Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498 quiz 499.
2. Surawicz, C.M., McFarland, L.V., Greenberg, R.N., Rubin, M., Fekety, R., Mulligan, M.E., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 (2000), 1012–1017.
3. Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A.M., Graninger, W., Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22 (1996), 813–818.
4. Al-Nassir, W.N., Sethi, A.K., Nerandzic, M.M., Bobulsky, G.S., Jump, R.L., Donskey, C.J., Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 47 (2008), 56–62.
5. Sunenshine, R.H., McDonald, L.C., Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73 (2006), 187–197.
6. Khoruts, A., Sadowsky, M.J., Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol, 2016.
7. Cammarota, G., Ianiro, G., Tilg, H., Rajilic-Stojanovic, M., Kump, P., Satokari, R., et al. European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66:4 (2017), 569–580.
8. Bakken, J.S., Borody, T., Brandt, L.J., Brill, J.V., Demarco, D.C., Franzos, M.A., et al., Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9 (2011), 1044–1049.
9. Smith, M., Kassam, Z., Edelstein, C., Burgess, J., Alm, E., OpenBiome remains open to serve the medical community. Nat Biotechnol, 32, 2014, 867.
10. Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C., et al., Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455.
11. Polage, C.R., Gyorke, C.E., Kennedy, M.A., Leslie, J.L., Chin, D.L., Wang, S., et al. Overdiagnosis of Clostridium difficile infection in the molecular test Era. JAMA Intern Med 175 (2015), 1792–1801.
12. Jalanka, J., Mattila, E., Jouhten, H., Hartman, J., de Vos, W.M., Arkkila, P., et al. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med, 14, 2016, 155.
13. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
14. Fuentes, S., van Nood, E., Tims, S., Heikamp-de Jong, I., ter Braak, C.J., Keller, J.J., et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J 8 (2014), 1621–1633.